Company / Current Liabilities
Syndax Pharmaceuticals Inc Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$120.1M
FY2025
5-year range
$20.7M / $120.1M
FY2021-FY2025
Trend
+16.0%
vs FY2024
Sector context
#87 of 213
Health Care
What the data says
At $120M, Syndax Pharmaceuticals Inc's current liabilities ranks #127 of 213 in the Health Care sector. Current Liabilities has increased for 9 consecutive years, from $10M in FY2016 to $120M in FY2025.
Based on SEC 10-K filings.
$120M in FY2025 with a 5-year CAGR of +44.8%.
Increased from $58M to $120M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +60.5%
- 5-Year CAGR
- +44.8%
- 10-Year CAGR
- -
Sector benchmark
#127 of 213 in Health CareTop 59% of 213This company $120.1M Sector average $1.6B
▼
-92.4% below sector average
Key checks
Key Insights
- Syndax Pharmaceuticals Inc's current liabilities has grown for 9 consecutive years.
- 5-year CAGR of +44.8%, indicating consistent growth.
- In FY2025, current liabilities increased 16.0% year-over-year.
- Ranks #87 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $120.1M | +16.0% |
| FY2024 | $103.5M | +78.2% |
| FY2023 | $58.1M | +99.9% |
| FY2022 | $29.1M | +40.5% |
| FY2021 | $20.7M | +9.6% |
| FY2020 | $18.9M | +2.7% |
| FY2019 | $18.4M | +14.1% |
| FY2018 | $16.1M | +1.9% |
| FY2017 | $15.8M | +52.4% |
| FY2016 | $10.4M | +113.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026